Anticancer treatments are increasingly relying on the use of targeted therapies[17] and we have previously shown that targeting the PI3K/AKT/mTOR pathways in HNSCC shows considerable anticancer activity in xenotransplant models of HNSCC[13]. Here, AKT1 is linked to head and neck squamous cell carcinoma.